Clinical Trial Update: A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating multiple oral doses of OPC-167832 for uncomplicated pulmonary tuberculosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Tuberculosis

Drugs mentioned

• OPC-167832 (OPC-167832)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Pulmonary TB | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-11-18